Aptus Pharma Limited has announced the successful completion of its postal ballot process, with shareholders approving two significant resolutions through remote e-voting on April 25, 2026. The proposals, which sought approval for increasing the company's authorized share capital and issuing bonus shares, received overwhelming support from voting members.

The postal ballot notice was dated March 24, 2026, with remote e-voting commencing on March 27, 2026, at 09:00 A.M. and concluding on April 25, 2026, at 05:00 P.M. A total of 337 shareholders were on record as of the cut-off date of March 24, 2026. The voting process was conducted through Central Depository Services Limited (CDSL) and scrutinized by CS Nalin T. Ganatra, a practicing company secretary appointed for this purpose.

Voting Results Overview

The two resolutions put to vote were both ordinary resolutions and neither had any interest from the promoter or promoter group. The voting participation showed strong engagement from shareholders, with 51,22,000 valid votes cast across both resolutions. All votes were cast in favor, with no votes against and no invalid or abstained votes recorded.

Resolution 1: Capital Increase

The first resolution sought approval for increasing the authorized share capital and consequent alteration to the capital clause of the Memorandum of Association. The promoter and promoter group held 50,00,000 shares and cast all 50,00,000 votes in favor through e-voting. Public non-institutional shareholders held 18,60,000 shares, with 1,22,000 votes polled, all in favor of the resolution.

Resolution 2: Bonus Share Issue

The second resolution proposed issuing bonus shares in the ratio of 3:2, meaning three bonus equity shares for every two existing fully paid-up equity shares held by members. The voting pattern mirrored the first resolution, with the promoter group casting all 50,00,000 votes in favor and public non-institutional shareholders contributing 1,22,000 votes in favor.

Both resolutions have been deemed passed with requisite majority as of April 25, 2026, the last date of remote e-voting. The scrutinizer's report confirmed that the voting process was conducted in a fair and transparent manner, with all relevant records maintained for safe custody. The results will be available on the company's website at aptus-pharma.com.

Aptus Pharma Limited has formally notified the BSE about an upcoming board meeting scheduled for April 27, 2026, where directors will deliberate on the company's audited financial results for the year ended March 31, 2026. The pharmaceutical company made this announcement on April 20, 2026, in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting Details

The meeting agenda includes consideration and approval of the company's audited financial results for the year ended March 31, 2026. Additionally, the board will take on record the auditor's report accompanying these financial results.

Trading Window Closure

In accordance with the company's Code of Conduct for Prohibition of Insider Trading and SEBI regulations, Aptus Pharma has implemented a trading window closure. The trading window for dealing in the company's securities has been closed and will remain closed until 48 hours after the declaration of the financial results.

Regulatory Compliance

The notification was issued pursuant to Regulation 29(1)(a) read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Tejash Maheshchandra Hathi, bearing DIN 03151221, signed the official communication to BSE Limited on April 20, 2026.

Company Information

Aptus Pharma Limited operates from its registered address in Ahmedabad, Gujarat, and trades on BSE under scrip code 544529. The company maintains its corporate presence in the pharmaceutical sector with established communication channels for investor relations and regulatory compliance.